Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 22 · below the Ichimoku cloud · RSI 35 · MACD below its signal · 6% above its 52-week low
| 14.76 | 52-week high | +65.61% |
| 11.35 | Previous month high | +27.35% |
| 9.64 | R3 (classic) | +8.16% |
| 9.39 | R2 (classic) | +5.36% |
| 9.23 | Previous week high | +3.56% |
| 9.15 | R1 (classic) | +2.66% |
| 9.14 | Previous day high | +2.55% |
| 8.91 | Price now | |
| 8.90 | Pivot | −0.14% |
| 8.66 | S1 (classic) | −2.83% |
| 8.65 | Previous day low | −2.95% |
| 8.41 | S2 (classic) | −5.64% |
| 8.40 | Previous week low | −5.75% |
| 8.40 | Previous month low | −5.75% |
| 8.40 | 52-week low | −5.75% |
| 8.17 | S3 (classic) | −8.33% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $302.9K | 0.00% | 29.42K | +5.0% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DXR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 27, 2026 | Jefferies John M.D.Officer | Stock Award(Grant) at price 0.00 per share. | 2.5K | — |
| Jun 22, 2026 | Michel Robert JChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 12K | — |
| Jun 22, 2026 | Feldschuh Michael RichardChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 30K | — |
| Jun 22, 2026 | Feldschuh Jonathan AdamOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Apr 7, 2026 | Feldschuh Michael RichardChief Executive Officer | Purchase at price 9.07 per share. | 1K | $9.07K |
| Mar 30, 2026 | Michel Robert JChief Financial Officer | Purchase at price 9.90 per share. | 1K | $9.90K |
| Mar 19, 2026 | Jefferies John M.D.Officer | Purchase at price 10.94 per share. | 5.9K | $65.00K |
| Dec 8, 2025 | Michel Robert JChief Financial Officer | Purchase at price 12.50 per share. | 3K | $37.50K |
| Dec 8, 2025 | Feldschuh Jonathan AdamOfficer and Director | Purchase at price 12.50 per share. | 18K | $225.00K |
| Nov 11, 2025 | Jefferies John M.D.Officer | Purchase at price 12.80 per share. | 2.3K | $30.00K |
| Apr 3, 2025 | Feldschuh Michael RichardChief Executive Officer | Purchase at price 7.89 per share. | 2.1K | $16.28K |
| Mar 9, 2025 | Michel Robert JChief Financial Officer | Purchase at price 8.00 per share. | 1K | $8.00K |
| Mar 9, 2025 | Feldschuh Michael RichardChief Executive Officer | Purchase at price 7.68 per share. | 3.4K | $25.80K |
| Dec 5, 2024 | Feldschuh Michael RichardChief Executive Officer | Purchase at price 8.89 per share. | 45K | $400.05K |
| Dec 5, 2024 | Feldschuh Jonathan AdamOfficer and Director | Purchase at price 8.89 per share. | 32K | $284.48K |
TimeframesDown on the daily and weekly, mixed on the hourly and monthly.
bouncing over the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -9.9 | -10.8 | -18.5 | 11.7 | -4.8 | 0.1 | 2.0 | -4.0 | 11.6 | -18.2 | -3.1 | −39.6% | |
| 2025 | 0.0 | -1.7 | 7.4 | -9.1 | 9.8 | 20.9 | 1.3 | 10.9 | 25.2 | -3.2 | -0.2 | 10.9 | +91.8% |
| 2024 | -9.5 | -9.2 | 12.7 | 8.9 | -9.5 | 6.4 | -5.2 | -4.4 | 2.4 | 0.1 | 11.0 | -20.0 | −19.9% |
| 2023 | -6.1 | -3.5 | 32.5 | 4.0 | -16.1 | 0.0 | 2.7 | -2.0 | -2.9 | -14.8 | -1.9 | 22.4 | +4.8% |
| 2022 | -6.7 | 1.1 | 0.0 | 7.8 | 10.0 | 4.5 | 5.8 | -1.6 | -3.6 | -12.7 | -17.8 | -3.7 | −18.9% |
| 2021 | 8.0 | -11.9 | 1.7 | -19.7 | -3.8 | 13.4 | -14.2 | 5.6 | 21.7 | -7.4 | 1.8 | 2.6 | −9.7% |
| 2020 | -1.5 | -7.1 | 56.9 | 17.3 | -15.8 | 10.1 | 17.6 | -6.4 | -2.5 | -7.6 | -11.3 | -3.1 | +33.0% |
| 2019 | 78.8 | 31.4 | -41.6 | -15.7 | -12.2 | -4.6 | 15.0 | -1.8 | 7.1 | -3.6 | 1.4 | 0.0 | +14.6% |
| 2018 | -3.3 | -18.6 | 166.1 | -28.0 | 4.5 | -7.6 | -20.4 | -6.4 | 0.8 | 32.4 | -4.2 | 29.3 | +79.4% |
| 2017 | -2.1 | 10.3 | -16.9 | -3.1 | -5.2 | -8.8 | -4.0 | -11.4 | -3.0 | -19.0 | 22.0 | -9.5 | −44.5% |
| 2016 | 0.7 | 5.2 | -0.4 | 0.5 | -0.7 | 1.3 | -0.2 | -1.0 | -1.6 | 3.2 | 4.7 | -3.1 | +8.4% |
| 2015 | -12.3 | 10.6 | -16.0 | 34.6 | -5.4 | -5.5 | -6.6 | -4.4 | 41.3 | 2.0 | -4.8 | -9.5 | +8.9% |
| 2014 | 0.4 | 3.4 | 16.5 | 0.6 | -7.1 | -10.6 | 1.7 | -0.9 | -11.1 | 4.5 | -2.6 | 10.8 | +2.2% |
| 2013 | 2.4 | -2.6 | -4.4 | 5.4 | -5.6 | 4.4 | -4.4 | -1.0 | -0.6 | 4.5 | -2.8 | -5.1 | −10.1% |
| 2012 | 4.0 | -1.0 | -3.4 | 1.1 | -3.2 | 0.0 | 2.9 | -3.5 | -5.9 | -3.5 | -2.8 | -2.2 | −16.5% |
| 2011 | 2.1 | 14.0 | -4.7 | -2.1 | 11.4 | -8.9 | -1.1 | 4.8 | 0.1 | -2.5 | -7.8 | -4.2 | −1.6% |
| 2010 | -5.1 | 8.5 | -9.1 | -0.6 | -7.1 | -3.3 | -2.4 | -4.3 | -2.3 | -0.9 | 8.2 | -6.1 | −23.2% |
| 2009 | 3.8 | -0.8 | -1.6 | -11.4 | -20.8 | -5.9 | -2.9 | 18.5 | -1.2 | 15.7 | 8.9 | -18.3 | −21.8% |
| 2008 | -10.1 | -20.9 | 28.2 | 3.5 | 5.8 | 8.6 | 12.6 | 3.8 | -12.6 | -4.6 | 5.2 | -5.2 | +5.3% |
| 2007 | -10.3 | -0.2 | -0.3 | -0.5 | 12.1 | 3.0 | 5.4 | 6.9 | -8.3 | 1.8 | -0.3 | -8.5 | −1.5% |
Buy / hold / sell counts
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.